We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App





New Technology Halves Time Currently Taken to Identify If Positive COVID-19 Sample Contains Variant of Concern

By LabMedica International staff writers
Posted on 01 Apr 2021
A groundbreaking new technology to rapidly detect new COVID mutations indicating whether positive test samples contain known variants is being trialed by the UK government.

The technology - known as ‘genotype assay testing’ - is being trialed by the UK government in NHS Test and Trace (England) laboratories is set to halve the time it currently takes to identify if a positive COVID-19 sample contains a variant of concern, and could be used in addition to standard testing for COVID-19 to identify cases quickly.

The new technology will mean that cases of variants of concern are detected faster than before - potentially halving the time it takes to detect a case, which is currently around four to five days for genomic sequencing. More...
By notifying those affected more quickly, this could allow contacts of positive cases to be traced sooner, breaking the chains of transmission, stop the spread of variants and saving lives.

Genotype assays would complement existing surveillance work that uses genomic sequencing to look for variants in COVID-positive samples. Genomic sequencing surveillance will continue to detect new variants and mutations. Where new variants or mutations are identified, the technology could be adapted to test for them as well, meaning the technology can be easily deployed to track the variants of most concern.

“Innovation is at the heart of our fight against COVID-19 and has a key part to play in controlling the spread of the virus. We must not stand still if we are to beat COVID-19 and safely ease restrictions in the coming months,” said UK Health and Social Care Secretary Matt Hancock. “That is why our goal is to eventually test every COVID positive sample for mutations, that indicate known variants, using this ground breaking new technology. This type of testing will help us rapidly identify variant cases and trace contacts quicker than ever before, helping stop outbreaks in their tracks and ensuring we can continue to follow the roadmap we have set out to get back to normal life.”

Related Links:
NHS Test and Trace


Platinum Member
Fully Automatic ACLIA Analyzer
MAGLUMI X8
Gold Member
Universal Transport Solution
Puritan®UniTranz-RT
Thyroid Test
Anti-Thyroid EIA Test
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: The method combines ultrasonic and fluorescence techniques to track amyloid aggregation in real time (Image Credit: Shutterstock)

Blood Test Measures Amyloid Seeding Activity to Detect Alzheimer’s Disease

Early, accurate diagnosis of Alzheimer’s disease (AD) remains challenging in routine practice, despite its role as the leading cause of dementia worldwide. Confirmation typically relies on cerebrospinal... Read more

Pathology

view channel
Image: TRUECAM automatically eliminates ambiguous or uninformative regions in whole-slide pathology images, enhancing the reliability of diagnostic analysis. (Photo courtesy of PolyU)

AI-Pathologist Framework Improves Accuracy and Reliability in Cancer Diagnosis

Ensuring reliable cancer diagnosis from digital pathology remains a critical challenge as clinical decisions rely on accurate slide interpretation. While artificial intelligence (AI) has accelerated whole-slide... Read more

Industry

view channel
Image: HealthTab will distribute the Abbott Afinion 2 Analyzer to NHS-linked pharmacies for hemoglobin A1c (HbA1c) and lipid profile testing. (Photo courtesy of Abbott)

New Collaboration Expands Point-of-Care Testing Across UK Community Pharmacies

HealthTab, a wholly owned subsidiary of Avricore Health, has entered a formal collaboration agreement with Abbott to supply and distribute Abbott’s point-of-care testing products in the UK through the... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.